|
March 13, 2008 -- Last
year in the U.S. and every year since 1984, more women than
men have died of heart disease. Surprised? Most women are.
An estimated seven million American women are currently living
with coronary heart disease and more than four million women
suffer from angina, or chest pain due to coronary heart disease.
Anginal pain may be brought on by the
simplest tasks, such as getting up from a chair, taking a short
walk, or even stress.
These women are limited in their daily activities and often
have different angina symptoms than men. Women with chronic
angina are more likely to experience unusual fatigue, sleep
disturbances, gastrointestinal symptoms or shortness of breath.
Over 25 hospitals across the United States
are currently participating in the AWARE
clinical study to evaluate the
effects
of Generx™ (Ad5FGF-4)
in women with recurrent angina who are not candidates for revascularization
and who are
receiving optimal drug therapy. The AWARE study is a women-only
cardiovascular
clinical study and reflects a growing awareness that heart
disease in women is a major health issue. For more information
about the AWARE trial, log onto the trial site at ClinicalTrials.gov.
About Generx
Generx is an
investigational product currently being studied for its effectiveness,
compared
to a placebo-control, to treat myocardial ischemia. Myocardial
ischemia, which results from insufficient blood flow
within the heart muscle, gives rise to the angina symptoms
associated
with coronary heart disease. Generx represents a new
therapeutic class of biologics that may promote angiogenesis,
a natural
process of blood vessel growth within the heart muscle,
to provide improved blood flow following a one-time intracoronary
administration from a standard cardiac infusion catheter.
Angioplasty.Org recommends that women
who are interested in this study contact the study investigator
in their locale, using the AWARE
Trial Study Locator. The investigator
will be able to
discuss
this potential
new approach
to the
treatment
of
angina.
|
